TxCell

CAR-T expert Li Zhou added to TxCell’s staff

Friday, October 14, 2016

TxCell, a biotechnology company developing innovative, personalized cellular immunotherapies using regulatory T cells (Treg) to treat severe chronic inflammatory and autoimmune diseases, has appointed Li Zhou, Ph.D., vice president, Cell Engineering. Dr. Zhou brings extensive pharmaceutical experience in antibody engineering and T-cell engineering to strengthen and accelerate the development of TxCell’s ENTrIA CAR-Treg platform.

[Read More]

Col-Treg gets FDA Orphan designation for uveitis

Monday, September 14, 2015

TxCell, a France-based biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announced today that the FDA’s Office of Orphan Products Development has granted Orphan Drug designation to TxCell’s Col-Treg, a personalized T cell immunotherapy using collagen-II specific regulatory T-cells, for the treatment of chronic non-infectious uveitis. The move followed the Orphan Drug designation already received for the product in Europe.

[Read More]

TxCell, Ferring collaborate on Ovasave

Monday, January 5, 2015

TxCell, a biotechnology company developing personalized T cell immunotherapies for severe chronic inflammatory and autoimmune diseases, is collaborating with Ferring International Center on the development of TcCell’s lead product Ovasave for the treatment of inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis. TxCell, a spin-off of Inserm (France’s National Institute for Health and Medical Research) is located in the Sophia Antipolis technology park, Nice, France.

[Read More]

TxCell extends phase I/II trial for Crohn’s disease

Wednesday, May 18, 2011

TxCell, a biotechnology company developing cell-based immunotherapies for the treatment of severe chronic inflammatory diseases with high unmet medical need, will extend treatment of patients included in the Crohn’s disease phase I/II study (CATS1) with Ovasave, a type 1 regulatory T cell based immunotherapy.

[Read More]